Phase 4 N=75 Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania
Bipolar Disorder · Cannabis-Related Disorder
Primary: Change in Joints Per Week — -10.1; -10.7 joints
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=86 Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
Moderate to Severe Crohn's Disease
Primary: Percentage of Participants With Clinical Response at Day 4 — 61.63 percentage of participants
Phase 4 N=26 Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline of Systemic Markers of Bone Metabolism (C-terminal Peptide of Type 1 Collagen (CTx) and Amino-terminal Propeptide of Type-1 Procollagen (P1NP))…
Phase 4 N=75 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder
Borderline Personality Disorder
Primary: Suicide Attempts — 2; 1; 4; 1 suicide attempt
Phase 4 N=20 Comparison of Wound Bed Establishment in Facial Burns
Burns
Primary: Time to Wound Epithelialization — 37.4; 37.6 days — p=.0853
Phase 2 N=32 Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
Extensive-Stage Small-Cell Lung Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 0; 0; 0; 0 Participants
Phase 3 N=1,083 Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
Analgesia
Primary: Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 Milligram (mg) Immediate Release (IR) or Extended Release (ER)…
Phase 3 N=127 Fetal and Infant Effects of Maternal Buprenorphine Treatment
Neonatal Abstinence Syndrome
Primary: Fetal Heart Rate — 145.7; 143.3; 138.6; 136.3 beats per minute — p=0.001
Phase 3 N=204 Hepatitis B Challenge Dose in Adults (V232-059-10)
Hepatitis B
Primary: Percentage of Seroresponders Before and After the Challenge Vaccination — 45.5; 58.8; 85.2; 88.3 Percentage of participants
Phase 2 N=26 Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Median Progression-free Survival
Phase 4 N=6 Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
Nephrotoxicity
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2
Phase 2 N=50 Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Hepatocellular Carcinoma · Hepatoma
Primary: Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the…
Phase 2 N=21 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Time to Progression — 4.07 months
Phase 2 N=43 Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis
Acute Anterior Uveitis
Primary: Number of Responders at Day 15 — 14; 9 Participants
Phase 3 N=790 The Testosterone Trials in Older Men
Andropause
Primary: Sexual Function Trial - Change in Psychosexual Daily Questionnaire Question 4 (PDQ-Q4) From Baseline to Month 12 — 1.4; 1.4; 0.6; 0.1 units on the PDQ-Q4 scale — p=<0.001